{"entity":{"id":"thyramir-v2","kind":"drug","name":"ThyraMIR v2","aka":[],"tldr":"ThyraMIR v2 is a test from Interpace Biosciences that measures small RNA molecules in a thyroid nodule sample to help judge how likely it is to be cancer.","summary":"ThyraMIR v2 is Interpace Biosciences' microRNA-based endocrine cancer test, used with ThyGeNEXT on indeterminate thyroid nodules. Interpace reports that Labcorp was the largest customer for the pair in 2025 and the first half of 2026.","status":"established","asOf":"2026-11-04","links":[{"label":"SEC: Interpace Biosciences Form S-1/A, October 2026","url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315226049456/forms-1a.htm"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":["thyroid-fna-molecular"],"targets":[],"drugs":["thygenext"],"companies":["interpace-biosciences"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"modality":"Thyroid nodule microRNA expression test","mechanism":"An algorithmic, pairwise microRNA expression analysis that refines the malignancy risk of an indeterminate thyroid nodule when combined with the ThyGeNEXT mutation panel, as described by Interpace Biosciences.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/thyramir-v2/","neighbours":{"technology":[{"id":"thyroid-fna-molecular","kind":"technology","name":"Thyroid nodule FNA, Bethesda cytology & molecular classifiers","route":"/technologies/thyroid-fna-molecular/"}],"drug":[{"id":"thygenext","kind":"drug","name":"ThyGeNEXT","route":"/drugs/thygenext/"}],"company":[{"id":"interpace-biosciences","kind":"company","name":"Interpace Biosciences","route":"/companies/interpace-biosciences/"}]}}